XYL Q1 Earnings Call: Xylem Lifts Revenue Outlook Amid Tariff Pressures and Operational Restructuring

Yahoo

13-05-2025

Water technology company Xylem (NYSE:XYL) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 1.8% year on year to $2.07 billion. The company expects the full year's revenue to be around $8.75 billion, close to analysts' estimates. Its non-GAAP profit of $1.03 per share was 7.9% above analysts' consensus estimates.
Is now the time to buy XYL? Find out in our full research report (it's free).
Revenue: $2.07 billion vs analyst estimates of $2.04 billion (1.8% year-on-year growth, 1.5% beat)
Adjusted EPS: $1.03 vs analyst estimates of $0.95 (7.9% beat)
Adjusted EBITDA: $470 million vs analyst estimates of $403.7 million (22.7% margin, 16.4% beat)
The company lifted its revenue guidance for the full year to $8.75 billion at the midpoint from $8.65 billion, a 1.2% increase
Management reiterated its full-year Adjusted EPS guidance of $4.60 at the midpoint
Operating Margin: 11.2%, in line with the same quarter last year
Free Cash Flow was -$38 million, down from $15 million in the same quarter last year
Organic Revenue rose 3.3% year on year (7.1% in the same quarter last year)
Market Capitalization: $30.97 billion
Xylem's first quarter results reflected broad-based demand across its business segments, with management attributing performance to operational discipline, simplification initiatives, and continued progress in integrating recent acquisitions. CEO Matthew Pine underscored that the company's diversified water solutions portfolio and exposure to stable customer operating budgets helped Xylem navigate ongoing volatility, while productivity gains and targeted pricing actions offset inflation and mix challenges. Pine stated, "We are leaning into our high-impact culture, simplifying processes and systems, and reorienting our structure to improve customer focus."
Looking ahead, Xylem's leadership maintained its full-year earnings outlook and lifted its revenue guidance, citing a strong backlog, the effects of recent price increases, and anticipated benefits from ongoing restructuring. However, management also acknowledged uncertainty around tariffs and potential softening in demand later this year. CFO Bill Grogan explained, "We have pricing and supply chain programs in place designed to offset the majority of the impacts from the current tariff scheme," but noted that the ultimate demand response remains a key variable for the coming quarters.
Management highlighted that the first quarter's results were shaped by pricing discipline, productivity initiatives, and continued organizational changes. Several key business trends and market developments were discussed:
Pricing Strategies Offset Headwinds: Leadership attributed margin stability and revenue gains to swift implementation of both price increases and surcharges across the portfolio, mitigating inflation and tariff impacts.
Organizational Simplification Progress: The ongoing restructuring—moving to a more focused divisional model and streamlining management—was identified as a factor in improved productivity and customer responsiveness. Management reported that decision-making speed and focus had already improved across global teams.
Evoqua Integration Momentum: The integration of Evoqua, acquired in 2023, continues to deliver cost synergies ahead of plan and is now beginning to generate revenue synergies, particularly in industrial verticals like microelectronics and energy.
Tariff Mitigation Measures: Management detailed actions such as dual sourcing and reducing exposure to Chinese imports, alongside leveraging trade agreements like USMCA, to manage the incremental cost from tariffs. Pricing actions are expected to continue adapting to changes in the trade environment.
Segment-Specific Trends: Measurement & Control Solutions (MCS) saw mixed results due to energy/water mix, with management noting near-term margin pressure but expected normalization in the second half. Orders in Applied Water and Water Infrastructure were supported by building solutions and treatment demand, respectively, except for ongoing weakness in China.
Xylem's outlook for the year is shaped by expectations of continued demand resilience, execution of restructuring initiatives, and the uncertain effects of tariffs on pricing and end-market demand.
Tariff and Pricing Dynamics: Management expects ongoing tariffs to be manageable through further price actions and supply chain adjustments, but acknowledged some risk of demand softening in the second half of the year as higher prices work through the system.
Operational Restructuring Benefits: The simplification of Xylem's operating model is anticipated to yield further productivity gains and margin improvements, especially as segment leaders gain greater accountability and decision-making power.
M&A and Portfolio Optimization: Continued integration of acquisitions, such as Evoqua, and potential divestitures of non-core assets are expected to enhance Xylem's focus on advanced treatment and intelligent solutions, supporting both growth and profitability goals.
Deane Dray (RBC Capital Markets): Asked whether Xylem or its customers were prepositioning inventory ahead of tariffs and about assumptions for price elasticity; management replied there was minimal inventory pull-forward and that some demand decline is expected but is manageable.
Mike Halloran (Baird): Inquired about the mechanics and timing of price increases and surcharges, and their impact on the second quarter; CEO Pine explained that actions were already in place with effects skewed to the back half of the year.
Scott Davis (Melius Research): Questioned whether the current environment accelerates Xylem's M&A strategy and portfolio optimization; Pine confirmed active M&A pursuits and ongoing divestitures of non-core assets, emphasizing strategic fit and financial discipline.
Nathan Jones (Stifel): Asked how tariffs influence Xylem's competitive positioning and the impact of organizational realignment; management cited portfolio diversification and a new divisional structure as key strengths in facing economic and competitive pressures.
Sara Borodinski (Jefferies): Sought clarity on the trajectory of Measurement & Control Solutions margins and order growth; CFO Grogan indicated that margin pressure from mix would bottom in the second quarter and improve sequentially, with order activity expected to normalize in the second half.
Looking forward, the StockStory team will closely monitor (1) the extent to which Xylem's price increases affect customer demand, particularly in the second half of the year as tariff impacts flow through, (2) the pace and effectiveness of operational restructuring and integration of Evoqua, and (3) order trends in Measurement & Control Solutions and Water Infrastructure segments. Developments in global trade policy and the company's ability to execute on M&A and portfolio optimization will also be important to track.
Xylem currently trades at a forward P/E ratio of 26.7×. In the wake of earnings, is it a buy or sell? Find out in our free research report.
Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.